| Session 1 - |
Cardiovascular Focus - Atherosclerosis Imaging Technologies |
| 8:15 - 8:45 AM |
Quantitative Coronary Arteriography to Assess the Effect of Pharmacologic Agents on the Progression/Regression of Coronary Atheroslcerosis
David Waters, MD, University of California, San Francisco |
| 8:45 – 9:15 AM |
Intravascular Ultrasound
Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal |
| 9:15 – 9:45 AM |
Carotid Intima Media Thickness: Use in Cardiovascular Risk
Assessment and in Clinical Trials
Eva Lonn, MD, McMaster University |
| 9:45 – 10:15 AM |
Carotid Ultrasound Phenotypes: Assessing Atherosclerosis Burden and Response to Therapy
J. David Spence, MD, Robarts Research Institute |
| 10:15 – 10:30 AM |
BREAK |
| 10:30 – 11:00 AM |
Magnetic Resonance Imaging
Alan Moody, MD Sunnybrook Health Sciences Centre |
| 11:00 – 11:30 PM |
Computed Tomography and Positron Emission Tomography
Zahi Fayad, MD, Mount Sinai School of Medicine |
| 11:30 – 12:00 PM |
PET as a Tool For Molecular Imaging
Robert Beanlands, MD, University of Ottawa Heart |
| 12:00 – 12:30 PM |
LUNCH |
| 12:30 – 1:30 PM |
Panel Discussion
Peter Libby, MD, Brigham and Women’s Hospital, Harvard Medical School
Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal
David Waters, MD, University of California, San Francisco
J. David Spence, Robarts Research Institute
Alan Moody, MD Sunnybrook Health Sciences Centre
Zahi Fayad, MD, Mount Sinai School of Medicine
Robert Beanlands, MD, University of Ottawa Heart
Eva Lonn, MD, McMaster University |
| 1:30 – 2:00 PM |
New Developments in Atherosclerosis Imaging Technologies
Philippe L. L’Allier, MD, Montreal Heart Institute |
| 2:00 – 2:30 PM |
Cardiovascular Imaging Initiatives
Peter Liu, MD, Canadian Institutes of Health Research |
| 2:30 – 3:00 PM |
Rewards and Risks of Using Surrogate Endpoints in the Approval of Drugs
Agnes V. Klein, MD, Health Canada |
| 3:00 – 3:30 PM |
Panel Discussion
Peter Libby, MD, Brigham and Women’s Hospital, Harvard Medical School
Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal
Philippe L’Allier, MD, Montreal Heart Institute
Peter Liu, MD, Canadian Institutes of Health Research
Agnes Klein, MD, Health Canada |
| 3:30 – 4:00 PM |
BREAK |
| Session 2 - |
New Frontiers in Imaging Biomarkers - Molecular Imaging Technologies |
| 4:00 – 4:30 PM |
Molecular Imaging Innocations in Cardiovascular Disease
Peter Libby, MD, Brigham and Women’s Hospital, Harvard Medical School |
| 4:30 – 5:00 PM |
|
| 5:00 – 5:30 PM |
|
| 5:30 – 6:00 PM |
An Approach to the Commercial Development of Molecular Imaging Agents
Allison Mueller, Director, GE Healthcare |
| 6:00 – 6:30 PM |
DINNER |
| 6:30 – 8:00 PM |
Panel Discussions: Academia, Industry and Regulatory Agency:
Working Together For the Future
Faculty Members |
| |
Atherosclerosis Imaging Technologies as Surrogate Endpoints: Perspectives
Catriona McMahon, M.D. |
| |
|
Secondary Content
About CMOD
CMOD is a 501(c)3 non-profit organization established in 2006 to advance the science of biomarkers used to identify, monitor and treat cardiovascular and related diseases.
|
about us